NATCOPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.1
| Stock Code | NATCOPHARM | Market Cap | 20,293 Cr. | Current Price | 1,132 ₹ | High / Low | 1,135 ₹ |
| Stock P/E | 13.5 | Book Value | 462 ₹ | Dividend Yield | 0.53 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,022 ₹ | DMA 200 | 949 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 65.2 | MACD | 28.6 | Volume | 6,16,143 | Avg Vol 1Wk | 6,48,085 |
| Low price | 752 ₹ | High price | 1,135 ₹ | PEG Ratio | 0.09 | Debt to equity | 0.03 |
| 52w Index | 99.2 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 30.9 |
📊 NATCOPHARM presents strong fundamentals with excellent ROE (27.5%) and ROCE (31.8%), supported by very low debt-to-equity (0.03). The stock trades at an attractive P/E (13.5 vs industry 30.9), suggesting undervaluation. EPS of 83.8 ₹ is robust, and PEG ratio (0.09) indicates strong growth potential relative to valuation. However, recent quarterly profit decline (PAT 107 Cr vs 501 Cr, -14.4% variation) raises short-term concerns. Technicals show bullish momentum (RSI 65.2, MACD 28.6) with price above DMA 50 and DMA 200, but the stock is near its 52-week high.
💡 Entry Price Zone: Ideal accumulation range is between 1,000 ₹ – 1,080 ₹, closer to DMA support levels, offering better risk-reward.
📈 Exit Strategy / Holding Period: If already holding, maintain a long-term horizon (3–5 years) given strong efficiency and undervaluation. Consider partial profit booking near 1,130 ₹–1,150 ₹ resistance zone. Long-term investors should hold, provided earnings stabilize and growth sustains.
✅ Positive
- Strong ROE (27.5%) and ROCE (31.8%) show efficient capital usage.
- Low debt-to-equity (0.03) ensures financial stability.
- Attractive P/E (13.5) compared to industry average (30.9).
- PEG ratio (0.09) indicates undervaluation relative to growth.
- FII holdings increased (+2.21%), showing foreign investor confidence.
⚠️ Limitation
- Quarterly profit decline (PAT 107 Cr vs 501 Cr).
- Dividend yield of 0.53% is modest.
- Stock trading near 52-week high, limiting immediate upside.
📉 Company Negative News
- Quarterly profit variation (-14.4%) raises short-term concerns.
📈 Company Positive News
- FII holdings increased (+2.21%), showing strong foreign support.
- DII holdings also slightly increased (+0.07%).
🏭 Industry
- Industry P/E at 30.9 indicates sector is moderately valued compared to NATCOPHARM.
- Pharmaceutical sector benefits from rising demand for generics and specialty drugs globally.
🔎 Conclusion
NATCOPHARM is fundamentally strong with excellent efficiency metrics, low debt, and attractive valuations, making it a good candidate for long-term investment. Fresh entry is attractive near 1,000 ₹–1,080 ₹. Existing holders should maintain positions with a 3–5 year horizon, booking profits near resistance levels while monitoring earnings stability and growth momentum.